Cipla vs Apollohosp Q2 FY25

Cipla reported Q2 FY25 revenue of INR 7,051 crore (+9% YoY) and an EBITDA margin of 26.7% (highest ever, +70bps YoY), driven by strong profitability in India chronic therapies and Africa growth. PAT stood at INR 1,303 crore (18.5% of sales). One India grew 5% YoY, impacted by weak acute season, but chronic therapies outpaced market. North America revenue was $237 million, with lanreotide franchise at 35% market share but facing supply issues expected to resolve by Q4. Africa grew 22% with South Africa private market ranking #2. Management maintained EBITDA margin guidance of 24.5%-25.5% for FY25. Key risks include lanreotide supply disruption, Goa FDA classification uncertainty, and potential pricing erosion in US generics.

Guidance read

EBITDA margin guidance maintained at 24.5%-25.5% for FY25: Management reiterated full-year EBITDA margin guidance despite Q2 margin of 26.7%, expecting normalized Q3 and Q4. Generic Advair launch expected in H1 FY2026: Risking of generic Advair progressing as per expectations; launch targeted for first half of fiscal 2026. Lanreotide supply issues to resolve by end of Q3, recovery in Q4: Supply challenges expected to be resolved by end of Q3, with sharp recovery in lanreotide franchise from Q4 FY25. One India to outpace market growth on full-year basis: Management expects India business to revert to growth trajectory with respiratory uptick in Q3 and outpace market growth for the full year.

Risk read

Key risks include Lanreotide supply disruption — Supply issues at partner site will reduce Q3 lanreotide sales significantly; recovery depends on partner's production ramp-up.; Goa facility FDA classification uncertainty — Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.; US generic pricing erosion — Blended US price erosion of ~10% YoY, with potential for further pressure from new competition in Albuterol and other products.; India acute season weakness — Slow seasonal growth in acute category, especially anti-infectives, impacted India business; recovery dependent on respiratory season..

Promise ledger

Of 2 tracked promises, management 0 met, 0 close, 2 missed.

Apollo Hospitals reported a strong Q2 FY25 with consolidated revenue of INR 5,589 crore (+15% YoY) and EBITDA of INR 816 crore (+30% YoY). PAT surged 63% YoY to INR 379 crore, driven by broad-based volume growth and margin improvement. Healthcare services revenue grew 14% to INR 2,903 crore, with occupancy rising to 73% (vs 68% last year). Apollo HealthCo turned profitable for the first time (PAT INR 19 crore). Management guided for 1,400 new beds in FY26, with phased commissioning to protect margins. The 24/7 platform is pivoting to sustainable growth, targeting breakeven in 5-6 quarters. Risk: Bangladesh patient flow disruption and quick commerce competition may pressure near-term ARPOB and GMV growth.

Guidance read

1,400 new beds in FY26 with phased operationalization: Six facilities in key metros will be commissioned in FY26; half of the beds operationalized in FY26, rest in FY27 to protect margins. Apollo HealthCo online segment breakeven in 5-6 quarters: The online 24/7 platform is expected to achieve breakeven by Q2 FY26, with sustainable GMV growth and reduced marketing spend. Combined pharmacy revenue target of INR 25,000 crore in 3 years: Including Keimed, the pharmacy platform targets INR 25,000 crore revenue with 7-8% EBITDA margin. Healthcare services margin expansion of 50-60 bps in FY25: Management expects 50-60 bps margin expansion for the full year, lower than initial 100-150 bps due to Bangladesh headwinds.

Risk read

Key risks include Bangladesh patient flow disruption — International patient revenue from Bangladesh fell 27% in H1, impacting Tamil Nadu volumes. Recovery expected but uncertain.; Quick commerce competition pressuring 24/7 GMV — Quick commerce players are impacting non-Rx sales, delaying unit economics improvement. Management is rolling out 19-min delivery to counter.; Insurance payer pushback on pricing — Health insurers facing high claims ratios may exert pressure on hospital pricing. Management believes network strength mitigates this.; New bed commissioning may pressure margins — 1,400 new beds in FY26 could drag EBITDA margins by 1-1.2% during ramp-up, though management expects 12-14 month breakeven..

Promise ledger

Scorecard data is being built as historical quarters are processed.